HopeStage
Back to all studies
CompletedNCT04779216

Romosozumab and bone density in women with anorexia

About this title

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Read the official source — NCT04779216
Medication studyAges 20–60United StatesEating disorders
The study in practice

Understand this study

Who was this study for?

Listed age limits: 20 years to 60 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 20, 2021
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Karen Klahr Miller, MD
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 20 Years to 60 Years
Official registry ID
NCT04779216
Official title
Show the full official title

Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Karen Klahr Miller, MD.

Did this study involve medication?

Yes. The study involved medication, including Romosozumab Prefilled Syringe, Placebo and Zoledronic acid 5 mg.

Who was this study for?

Listed age limits: 20 years to 60 years.

Want to explore more studies?

Explore studies